U.S. Breast Cancer Diagnostics Market to 2032
Overview
The U.S. Breast Cancer Diagnostics Market is expected to reach a 3.52 USD Billion by 2032 and is projected to grow at a CAGR of 14.64% from 2025 to 2032.
Revenue, 2024 (USD Billion)
1.52
Forecast, 2032 (USD Billion)
3.52
CAGR, 2024 - 2032
14.64%
Report Coverage
U.S.
U.S. Breast Cancer Diagnostics Market 2018-2032 USD Billion
U.S. Breast Cancer Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 1.52 USD Billion
- Projected Market Size (2032): 3.52 USD Billion
- CAGR (2025-2032): 14.64%
Key Findings of U.S. Breast Cancer Diagnostics Market
- The U.S. Breast Cancer Diagnostics Market was valued at 1.52 USD Billion in 2024.
- The U.S. Breast Cancer Diagnostics Market is likely to grow at a CAGR of 14.64% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Invasive Ductal Carcinoma in Type Segment accounted for the largest share of the market with a revenue of 1.03 USD Billion
- The fastest growing segment Hospitals in End User Segment grew Fastest with a CAGR of 16.36% during the forecast period from 2024 to 2032.
U.S. Breast Cancer Diagnostics Market Scope
U.S. Breast Cancer Diagnostics Market Segmentation & Scope
Test
- Others
- Blood Test
- Genomic Test
- Biopsy
- Imaging
Type
- Metastatic Breast Cancer
- Inflammatory Breast Cancer
- Ductal Carcinoma In Situ
- Invasive Ductal Carcinoma
End User
- Others
- Research & Academic Institutes
- Clinics
- Diagnostic Centers
- Hospitals
Distribution Channel
- Others
- Retail Sales
- Direct Tenders
U.S. Breast Cancer Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 1.52 USD Billion |
| Market Value in 2032 | 3.52 USD Billion |
| CAGR (2025-2032) | 14.64% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Test,Type,End User,Distribution Channel |
Regional Insights:
-
Leading Market (2024-2032): U.S., leading in terms of revenue 1.52 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 1,518.80 USD Million in 2024.
Segments and Scope
-
U.S. Breast Cancer Diagnostics Market to 2032, By Test
- Imaging is the largest segment in U.S. Breast Cancer Diagnostics Market to 2032 with a revenue of 598.66 USD Billion in the year 2024.
- Imaging is the Fastest growing segment in U.S. Breast Cancer Diagnostics Market to 2032 with a Growth rate of 15.93 % in forecast period 2025-2032.
-
U.S. Breast Cancer Diagnostics Market to 2032, By Type
- Invasive Ductal Carcinoma is the largest segment in U.S. Breast Cancer Diagnostics Market to 2032 with a revenue of 1.03 USD Billion in the year 2024.
- Invasive Ductal Carcinoma is the Fastest growing segment in U.S. Breast Cancer Diagnostics Market to 2032 with a Growth rate of 15.10 % in forecast period 2025-2032.
-
U.S. Breast Cancer Diagnostics Market to 2032, By End User
- Hospitals is the largest segment in U.S. Breast Cancer Diagnostics Market to 2032 with a revenue of 601.98 USD Billion in the year 2024.
- Hospitals is the Fastest growing segment in U.S. Breast Cancer Diagnostics Market to 2032 with a Growth rate of 16.36 % in forecast period 2025-2032.
-
U.S. Breast Cancer Diagnostics Market to 2032, By Distribution Channel
- Direct Tenders is the largest segment in U.S. Breast Cancer Diagnostics Market to 2032 with a revenue of 928.12 USD Billion in the year 2024.
- Direct Tenders is the Fastest growing segment in U.S. Breast Cancer Diagnostics Market to 2032 with a Growth rate of 15.28 % in forecast period 2025-2032.
U.S. Breast Cancer Diagnostics Market Company Share Analysis
| Company Name |
|
||
| Koninklijke Philips N.V. | |||
| Abbott | |||
| Hologic, Inc. | |||
| Exact Sciences Corporation | |||
| F. Hoffmann-La Roche Ltd. | |||
U.S. Breast Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion
U.S. Breast Cancer Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The U.S. Breast Cancer Diagnostics Market is segmented based on Segmentation Test,Type,End User,Distribution Channel.
U.S. Breast Cancer Diagnostics Market was valued at USD 1.52(Revenue in USD Billion) in 2021.
U.S. Breast Cancer Diagnostics Market is projected to grow at a CAGR of 14.64% during the forecast period of 2024 to 2032.
The Invasive Ductal Carcinoma segment is expected to dominate the U.S. Breast Cancer Diagnostics Market, holding a largest market share of 1.03 USD Billion in 2024
U.S. Breast Cancer Diagnostics Market Scope
U.S. Breast Cancer Diagnostics Market Segmentation & Scope
Test
- Others
- Blood Test
- Genomic Test
- Biopsy
- Imaging
Type
- Metastatic Breast Cancer
- Inflammatory Breast Cancer
- Ductal Carcinoma In Situ
- Invasive Ductal Carcinoma
End User
- Others
- Research & Academic Institutes
- Clinics
- Diagnostic Centers
- Hospitals
Distribution Channel
- Others
- Retail Sales
- Direct Tenders
Frequently Asked Questions
The U.S. Breast Cancer Diagnostics Market is segmented based on Segmentation Test,Type,End User,Distribution Channel.
U.S. Breast Cancer Diagnostics Market was valued at USD 1.52(Revenue in USD Billion) in 2021.
U.S. Breast Cancer Diagnostics Market is projected to grow at a CAGR of 14.64% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Breast Cancer Diagnostics Market for final year is USD 3.52 (USD Billion).
U.S. Breast Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The U.S. Breast Cancer Diagnostics Market is segmented based on Segmentation Test,Type,End User,Distribution Channel.
U.S. Breast Cancer Diagnostics Market was valued at USD 1.52(Revenue in USD Billion) in 2021.
U.S. Breast Cancer Diagnostics Market is projected to grow at a CAGR of 14.64% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Breast Cancer Diagnostics Market for final year is USD 3.52 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.